SEC Form 4 · accession 0001179110-17-006413
ABBOTT LABORATORIES · ABT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel J Starks
Director
Period of report
Apr 28, 2017
Accepted (ET)
May 2, 2017 · 5:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000001800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common shares without par valueF1,F2 | Apr 28, 2017 | A | 3,437 | $0.00 | A | 6,462,940 | D | |
| Common shares without par valueF3 | holding | — | — | — | 258 | I | Alynne Starks 2012 Irrevocable Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
- F2Includes a St. Jude Medical, Inc. restricted stock unit award that was converted to an Abbott award of 58,399 restricted stock units in connection with Abbott's acquisition of St. Jude Medical, in a transaction exempt from Section 16 under Rule 16b-3. The restricted stock units are vested and will settle in shares on July 4, 2017.
- F3Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust.